Viking Therapeutics Says Obesity Drug Showed 'Superior' Results in Study; Shares Jump
MT Newswires Live
Sep 22
VikingTherapeutics (VKTX) said Tuesday its subcutaneous VK2735 showed "superior weight maintenance" under less frequent dosing regiments compared to placebo over a 12-week period in a clinical study.
Participants randomized to monthly dosing regimens preserved up to 90% of mean weight loss achieved during the induction period, the company said.
VK2735 also demonstrated an "encouraging safety and tolerability profile," Viking said.
The company said it plans to explore oral dosing regimens in part 2 of the study.
Shares of Viking Therapeutics were up more than 36% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.